by B2i | Nov 12, 2020 | Press Releases
Six new and expanded animal and human health collaborations since Q2 2020 Expanded presence in the Asia Pacific Region Important progress and expanded animal efficacy data in COVID-19 vaccine and antibody programs ZAPI to conduct additional animal studies for...
by B2i | Oct 29, 2020 | Press Releases
JUPITER, FL / October 29, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and...
by B2i | Oct 12, 2020 | Press Releases
C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators Record Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g/l in 5 days) Non-Exclusive...
by B2i | Sep 17, 2020 | Press Releases
LIANYUNGANG, CHINA and JUPITER, FL / September 17, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate...
by B2i | Sep 14, 2020 | Press Releases
JUPITER, FL / September 14, 2020 / Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1 gene expression platform to...
by B2i | Aug 13, 2020 | Press Releases
Entered into two new collaborations with top tier animal health companies Entered into a fully funded human health collaboration with a top five global pharmaceutical company Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal...
